|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:atccode
|
C07 AX
|
|
gptkbp:brand
|
gptkb:Vyndamax
|
|
gptkbp:clinical_trial
|
Phase 3
ATTR-ACT
|
|
gptkbp:code
|
0071-0930
|
|
gptkbp:contraindication
|
hypersensitivity to tafamidis
|
|
gptkbp:dosage_form
|
61 mg
|
|
gptkbp:drug_interactions
|
minimal
|
|
gptkbp:duration
|
long-term
|
|
gptkbp:effective_date
|
2019-05-24
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:capsule
|
|
gptkbp:healthcare
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vyndamax
|
|
gptkbp:indication
|
hereditary transthyretin amyloidosis
|
|
gptkbp:ingredients
|
gptkb:tafamidis
|
|
gptkbp:label
|
gptkb:Pfizer_Inc.
|
|
gptkbp:lifespan
|
approximately 30 hours
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:marketed_as
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:pharmacokinetics
|
highly protein-bound
stabilizes transthyretin protein
|
|
gptkbp:previous_name
|
gptkb:tafamidis
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_guidance_on
|
recommended for specific cases
|
|
gptkbp:related_products
|
gptkb:tafamidis_meglumine
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:research_focus
|
amyloidosis treatment
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:shelf_life
|
varies by batch
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
abdominal pain
diarrhea
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:structure
|
C19 H20 N2 O4 S
|
|
gptkbp:symbolism
|
yes
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:used_for
|
treatment of transthyretin amyloidosis
|
|
gptkbp:bfsParent
|
gptkb:tafamidis
|
|
gptkbp:bfsLayer
|
7
|